These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7690213)

  • 21. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
    Apostolopoulos V; Xing PX; McKenzie IF
    Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MHC-restricted presentation of a single repeat of MUC1 mucin.
    Orr MK; Burnside JS; Phillips CA; Philip R; Dombrowski KE; Wright SE
    Immunol Invest; 2007; 36(3):271-83. PubMed ID: 17558710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
    Ninkovic T; Hanisch FG
    J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1 peptide epitopes associated with five different H-2 class I molecules.
    Apostolopoulos V; Haurum JS; McKenzie IF
    Eur J Immunol; 1997 Oct; 27(10):2579-87. PubMed ID: 9368613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
    Burchell J; Taylor-Papadimitriou J
    Epithelial Cell Biol; 1993 Oct; 2(4):155-62. PubMed ID: 7505698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes.
    Beum PV; Singh J; Burdick M; Hollingsworth MA; Cheng PW
    J Biol Chem; 1999 Aug; 274(35):24641-8. PubMed ID: 10455130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucin-1-related T cell infiltration in colorectal carcinoma.
    Mulder WM; Stukart MJ; de Windt E; Wagstaff J; Scheper RJ; Bloemena E
    Cancer Immunol Immunother; 1996 Jul; 42(6):351-6. PubMed ID: 8830738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.
    Chen J; Li HY; Wang D; Zhao JJ; Guo XZ
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1509-18. PubMed ID: 21950745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of mucin gene expression in normal and neoplastic tissues.
    Ho SB; Niehans GA; Lyftogt C; Yan PS; Cherwitz DL; Gum ET; Dahiya R; Kim YS
    Cancer Res; 1993 Feb; 53(3):641-51. PubMed ID: 7678777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
    Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
    Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular biological analyses of mucin core proteins and their clinical application].
    Hinoda Y; Imai K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):150-6. PubMed ID: 8311484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.
    Kotera Y; Fontenot JD; Pecher G; Metzgar RS; Finn OJ
    Cancer Res; 1994 Jun; 54(11):2856-60. PubMed ID: 7514493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immunodominant epitope present in multiple class I MHC molecules and recognized by cytotoxic T lymphocytes.
    Mann DW; McLaughlin-Taylor E; Wallace RB; Forman J
    J Exp Med; 1988 Jul; 168(1):307-24. PubMed ID: 2456370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients.
    Nuti M; Rughetti A; Turchi V; Apollonj-Ghetti C; Scambia G; Frati L
    In Vivo; 1993; 7(6B):645-7. PubMed ID: 7514896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.
    Acres RB; Hareuveni M; Balloul JM; Kieny MP
    J Immunother Emphasis Tumor Immunol; 1993 Aug; 14(2):136-43. PubMed ID: 8280702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal heterogeneity in LFA-3 and ICAM-1 requirement for lysis by alloreactive T lymphocytes.
    Galocha B; López D; López de Castro JA
    J Immunol; 1993 Mar; 150(5):1653-62. PubMed ID: 7679690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.